TNDM vs. LIVN, WRBY, INSP, LQDA, LMAT, PRCT, AORT, EYE, ENOV, and CNMD
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), and CONMED (CNMD). These companies are all part of the "medical equipment" industry.
Tandem Diabetes Care vs. Its Competitors
LivaNova (NASDAQ:LIVN) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
LivaNova has a net margin of -16.13% compared to Tandem Diabetes Care's net margin of -20.51%. LivaNova's return on equity of 14.57% beat Tandem Diabetes Care's return on equity.
LivaNova has higher revenue and earnings than Tandem Diabetes Care. LivaNova is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
LivaNova has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
LivaNova presently has a consensus target price of $59.71, indicating a potential upside of 5.98%. Tandem Diabetes Care has a consensus target price of $22.44, indicating a potential upside of 84.00%. Given Tandem Diabetes Care's higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than LivaNova.
In the previous week, Tandem Diabetes Care had 7 more articles in the media than LivaNova. MarketBeat recorded 20 mentions for Tandem Diabetes Care and 13 mentions for LivaNova. Tandem Diabetes Care's average media sentiment score of 1.44 beat LivaNova's score of 1.26 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.
97.6% of LivaNova shares are held by institutional investors. 0.3% of LivaNova shares are held by insiders. Comparatively, 1.9% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
LivaNova beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
This page (NASDAQ:TNDM) was last updated on 9/12/2025 by MarketBeat.com Staff
Free TNDM Stock Alerts